FilingSEC EDGARS-8
Akari Therapeutics Files S-8 Registration Statement for Equity Incentive Plan
· SEC accepted
StageRegistration
Filing content
Akari Therapeutics filed an S-8 registration statement to register 144,000,000,000 additional ordinary shares issuable under its 2023 Equity Incentive Plan.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…